Recently, the US government's imposition of "reciprocal tariffs" on Chinese goods exported to the United States has garnered significant market attention. Several listed medical device companies have promptly responded, affirming that they have devised contingency plans and countermeasures. Industry experts opine that while the effects of tariff policies on the industrial chain are intricate and fluid, the long-term outlook for the trend towards independent controllability and overseas expansion of medical device products remains promising. According to data from the China Chamber of Commerce for Import and Export of Medicines and Health Products, China's exports of medical devices to the US are projected to reach US$11.758 billion by 2024, with most medical consumables and equipment being impacted. Nevertheless, numerous companies have indicated that the impact is manageable, having taken preemptive measures such as stockpiling supplies or establishing overseas production bases to mitigate the tariff effects.